Xe-133 decays by beta emission and gamma emission with a half-life of 5.24 days. It is typically produced in nuclear reactors by neutron irradiation of stable xenon-132. The resulting Xe-133 is a gas, which necessitates specialised handling and containment systems. Supply chain considerations involve the availability of nuclear reactors, xenon targets, and gas handling equipment. Logistical challenges include the safe containment and delivery of a radioactive gas. Accessibility for developing countries is limited by the specialised facilities and regulatory requirements.
Overview
Maturity
Xe-133 production and application are well-established, with use in nuclear medicine.
Safety considerations
Xe-133 is a radioactive gas that emits beta and gamma radiation, posing an inhalation hazard. Robust containment and ventilation systems are essential.
Security considerations
While Xe-133 is not a proliferation concern, proper control and monitoring are necessary to prevent unauthorised access or misuse.
Safeguarding considerations
Traditional IAEA safeguards are not directly applicable due to the absence of fissile materials. However, monitoring and verification of the production and use of Xe-133 may be considered to ensure transparency and prevent misuse.